Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialHertzel C. Gerstein, Anselmo P. Bordonava, Mark Lakshmanan et al.|The Lancet|2019Cited by 3.1k
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trialHertzel C. Gerstein, Anselmo P. Bordonava, Helen M. Colhoun et al.|The Lancet|2019Cited by 640